Due to the weakening of the US dollar and uncertainty in tariff policies, Merck has revised its full-year adjusted earnings forecast.

German pharmaceutical company Merck announced that adjusted EBITDA in the first quarter increased by 5.6% to 1.54 billion euros, slightly higher than analysts' expectations of 1.51 billion euros. The company has lowered its financial guidance, now estimating full-year adjusted EBITDA to be between 5.8 billion and 6.4 billion euros, lower than last year's 6.07 billion euros, in order to reflect the weakening of the US dollar and the uncertainty surrounding tariff policies.